Erratum: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study (Leukemia (2007) vol. 21 (627-632) 10.1038/sj.leu.2404562);Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study

Leukemia

Volumn 21, Issue 4, 2007, Pages 627-632

  Hedenus, M ^a   Birgegard G ^b   Nasman P ^c   Ahlberg, L ^d   Karlsson, T ^e   Lauri, B ^f   Lundin, J ^g   Larfars G ^h   Osterborg A ^g  

^a SUNDSVALL HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e ST GÖRAN S HOSPITAL   (Sweden)

^f SUNDERBY HOSPITAL   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SIDE EFFECT; THROMBOPHLEBITIS; TRANSFERRIN BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 33947405774     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405094     Document Type: Erratum

References (21)

1. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeild J, Bennett CL, Cella D et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-2320.
2. Bokemeyer C, Aapro MS, Courdi A, Foubent J, Link H, Österborg A. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: 2201-2216.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology - v.2.2006. Cancer- and treatment-related anemia. Version 2.2006. http://www.nccn.org/professionals/physician_gls/ f_guidelines.asp. Accessed April 19, 2006.
4. Roy CN, Andrews NC. Anemia of inflammation: The hepcidin link. Curr Opin Hematol 2005; 12: 107-111.
5. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26: 323-342.
6. Glaspy J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 1999; 13: 461-473.
7. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
8. Glaspy J, Beguin Y. Anaemia management strategies: Optimising treatment using epoetin beta (NeoRecormon). Oncology 2005; 69 (Suppl 2): 8-16.
9. Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P et al. Iron and the anaemia of chronic disease: A review and strategic recommendations. Curr Med Res Opin 2006; 22: 731-737.
10. Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int 1999; 69 (Suppl): S61-S66.
11. Locatelli F, Aljama P, Barany P, Canaud B, Carera F, Eckardt KU et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl 2): ii1-ii47.
12. Auerbach M, Ballard H, Trout RJ, McIlwain M, Ackerman A, Bahrain H et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
13. Henry DH. The role of intravenous iron in cancer-related anemia. Oncology (Williston Park) 2006; 20 (Suppl 6): 21-24.
14. Junca J, Fernandez-Aviles F, Oriol A, Navarro JT, Milla F, Sancho JM et al. The usefulness of the serum transferrin receptor in detecting iron deficiency in the anemia of chronic disorders. Haematologica 1998; 83: 676-680.
15. Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002; 99: 1489-1491.
16. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122: 386-393.
17. Österborg A, Brandberg Y, Molotova V, Iosava G, Abdulkadyrov K, Hedenus M et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486-2494.
18. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
19. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anemia of multiple myeloma. Br J Haematol 2001; 113: 172-179.
20. Besarab A, Frinak S, Yee J. An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 1999; 10: 2029-2043.
21. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nat Clin Pract Oncol 2006; 3: 152-164.